Radiotherapy is to irradiate the tumor site with high energy rays to kill the tumor cells. Currently, it is mainly localized radiation therapy involving fields. Radiotherapy plays an important role in some lymphoma subtypes such as T/NK cell lymphoma. However, radiotherapy has both immediate and long-term side effects. Common near-term side effects include skin reactions and decreased white blood cells. In recent years, targeted therapy has made breakthroughs in the treatment of lymphoma, especially B-type non-Hodgkin’s lymphoma, due to the introduction of monoclonal antibodies. The regimen of biologically targeted therapy combined with chemotherapy has resulted in significant extension of overall survival time and disease-free survival time for many lymphoma patients. Meroval, a landmark drug for the treatment of non-Hodgkin’s B-cell lymphoma, was approved by the FDA in 1997 and became the first monoclonal antibody drug for the treatment of non-Hodgkin’s lymphoma. Meroval binds exclusively to CD20-expressing B cells to kill tumor cells or induce apoptosis, which is highly targeted and basically does not affect normal cell growth, avoiding damage to normal cells and minimizing the damage of the drug to the body. Anti-CD20 monoclonal antibodies can also be combined with isotopes to treat lymphoma. The anti-CD20 monoclonal antibodies act as biological missiles, while the isotopes act as warheads that are guided to the tumor site for internal irradiation and specific killing of tumor cells. Some other target drugs, including: 1. histone deacetylase inhibitors: MGCD103Zolinza; 2. mTOR inhibitors: Temsirolimus, Everolimus, HSP-90 inhibitor 17AAG; 3. SYK inhibitors: R788; 4. microenvironmental modulators: thalidomide, ralidomide; 5. other monoclonal Antibodies: for example, anti-CD19, anti-CD22, anti-CD30, anti-CD52, anti-CD80, anti-CD52, anti-HLA-DR and other monoclonal antibodies. Interferon has a certain inhibitory effect on tumor cells, especially for low-grade malignant lymphoma, and IL-12 can also be used to treat lymphoma, especially cutaneous lymphoma. Immunotherapy: Immunotherapy + chemotherapy can achieve greater efficacy than the two alone, such as interferon + chemotherapy, melphalan + chemotherapy, 2, radiotherapy + chemotherapy: radiotherapy + chemotherapy can achieve greater efficacy than the two alone, and radiotherapy can be applied sequentially after chemotherapy. 3.Hematopoietic stem cell transplantation: Hematopoietic stem cell transplantation is divided into bone marrow stem cell transplantation, peripheral blood stem cell transplantation and umbilical cord blood stem cell transplantation according to the type. According to the transplantation method, there are autologous stem cell transplantation and allogeneic stem cell transplantation. Autologous stem cell transplantation is prone to relapse. Allogeneic stem cell transplantation has low recurrence rate and better treatment effect, but it requires high basic conditions of patients and high treatment cost, and there may be immune reaction of the graft to the patient. Surgical treatment: 1. mainly applied to biopsy; 2. splenectomy for splenomegaly combined with hypersplenism; 3. gastric lymphoma with ulcer prone to bleeding and perforation; 4. enteropathic T-cell lymphoma; 5. local residual masses that are difficult to eliminate after chemotherapy. Chinese medicine treatment: Chinese medicine treatment mainly consists of two highlights: supporting the positive and eliminating the evil and eliminating the evil and supporting the positive. Because the patient is sick because of positive deficiency, so supporting positive and detoxifying anti-cancer runs through the whole treatment of the disease. Softening and dispersing nodules, clearing heat and detoxifying, and activating blood circulation can have certain inhibitory effects on lymphoma, while supporting the positive can adjust the immune defense function of the body as a whole, and Chinese medicine can also slow down some side effects of chemotherapy drugs, such as nausea, vomiting, and other symptoms. We should apply the above treatments in a rational, planned and orderly manner to achieve the best therapeutic effect (including survival quality and cure rate) according to the patient’s pathological type (different pathological subtypes or subtypes have different treatments, different chemotherapy regimens, different drugs, different efficacy and prognosis), the biological characteristics of lymphoma, the stage and development trend of the disease, and the physical condition, instead of randomly applying and piling up the above treatments.